Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids

Kevin P. O'Boyle, Yuexian Wang, Edward L. Schwartz, Donna Lee Regl, Avi Israel Einzig, Janice P. Dutcher, Peter H. Wiernik, Susan Band Horwitz

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

BACKGROUND. Paclitaxel is an antimiotic agent isolated from the Pacific yew tree. It has demonstrated antitumor activity in several cancers and is the first of a new class of antineoplastic agents containing a taxane ring system. Its levels in serum and urine have been measured previously by high performance liquid chromatography (HPLC). In this study, the authors developed two competitive radioimmunoassay methods to determine whether they could reliably be used to measure levels of paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids. METHODS. A monoclonal antibody prepared against paclitaxel was employed in an immunoradiometric assay (IRMA), in which 125I-labeled antibody was used, and in a more conventional tritiated radioimmunoassay (RIA), in which 3H-paclitaxel was used. RESULTS. Both radioimmunoassays detected levels of paclitaxel in sera that were comparable to those observed with HPLC. However, the IRMA was the most sensitive. Only the IRMA was able to detect low levels of paclitaxel in cerebrospinal fluid after paclitaxel infusion and in sera 3 weeks after infusion. Both the IRMA and RIA methods were able to detect paclitaxel in ascitic and pleural fluids. CONCLUSIONS. Monitoring paclitaxel levels reliably in sera and other bodily fluids is possible with these radioimmunoassays and may be of value in predicting and preventing toxicity and optimizing paclitaxel treatments.

Original languageEnglish (US)
Pages (from-to)1022-1030
Number of pages9
JournalCancer
Volume79
Issue number5
DOIs
StatePublished - Mar 1 1997

Fingerprint

Ascitic Fluid
Paclitaxel
Radioimmunoassay
Immunoradiometric Assay
Serum
High Pressure Liquid Chromatography
Antineoplastic Agents
Cerebrospinal Fluid
Monoclonal Antibodies
Urine
Antibodies

Keywords

  • carcinoma patients
  • cerebrospinal fluid
  • monoclonal antibody
  • paclitaxel
  • radioimmunoassay

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids. / O'Boyle, Kevin P.; Wang, Yuexian; Schwartz, Edward L.; Regl, Donna Lee; Einzig, Avi Israel; Dutcher, Janice P.; Wiernik, Peter H.; Band Horwitz, Susan.

In: Cancer, Vol. 79, No. 5, 01.03.1997, p. 1022-1030.

Research output: Contribution to journalArticle

O'Boyle, Kevin P. ; Wang, Yuexian ; Schwartz, Edward L. ; Regl, Donna Lee ; Einzig, Avi Israel ; Dutcher, Janice P. ; Wiernik, Peter H. ; Band Horwitz, Susan. / Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids. In: Cancer. 1997 ; Vol. 79, No. 5. pp. 1022-1030.
@article{d6f436dfe3944d58a22eb4201143fc56,
title = "Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids",
abstract = "BACKGROUND. Paclitaxel is an antimiotic agent isolated from the Pacific yew tree. It has demonstrated antitumor activity in several cancers and is the first of a new class of antineoplastic agents containing a taxane ring system. Its levels in serum and urine have been measured previously by high performance liquid chromatography (HPLC). In this study, the authors developed two competitive radioimmunoassay methods to determine whether they could reliably be used to measure levels of paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids. METHODS. A monoclonal antibody prepared against paclitaxel was employed in an immunoradiometric assay (IRMA), in which 125I-labeled antibody was used, and in a more conventional tritiated radioimmunoassay (RIA), in which 3H-paclitaxel was used. RESULTS. Both radioimmunoassays detected levels of paclitaxel in sera that were comparable to those observed with HPLC. However, the IRMA was the most sensitive. Only the IRMA was able to detect low levels of paclitaxel in cerebrospinal fluid after paclitaxel infusion and in sera 3 weeks after infusion. Both the IRMA and RIA methods were able to detect paclitaxel in ascitic and pleural fluids. CONCLUSIONS. Monitoring paclitaxel levels reliably in sera and other bodily fluids is possible with these radioimmunoassays and may be of value in predicting and preventing toxicity and optimizing paclitaxel treatments.",
keywords = "carcinoma patients, cerebrospinal fluid, monoclonal antibody, paclitaxel, radioimmunoassay",
author = "O'Boyle, {Kevin P.} and Yuexian Wang and Schwartz, {Edward L.} and Regl, {Donna Lee} and Einzig, {Avi Israel} and Dutcher, {Janice P.} and Wiernik, {Peter H.} and {Band Horwitz}, Susan",
year = "1997",
month = "3",
day = "1",
doi = "10.1002/(SICI)1097-0142(19970301)79:5<1022::AID-CNCR20>3.0.CO;2-2",
language = "English (US)",
volume = "79",
pages = "1022--1030",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids

AU - O'Boyle, Kevin P.

AU - Wang, Yuexian

AU - Schwartz, Edward L.

AU - Regl, Donna Lee

AU - Einzig, Avi Israel

AU - Dutcher, Janice P.

AU - Wiernik, Peter H.

AU - Band Horwitz, Susan

PY - 1997/3/1

Y1 - 1997/3/1

N2 - BACKGROUND. Paclitaxel is an antimiotic agent isolated from the Pacific yew tree. It has demonstrated antitumor activity in several cancers and is the first of a new class of antineoplastic agents containing a taxane ring system. Its levels in serum and urine have been measured previously by high performance liquid chromatography (HPLC). In this study, the authors developed two competitive radioimmunoassay methods to determine whether they could reliably be used to measure levels of paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids. METHODS. A monoclonal antibody prepared against paclitaxel was employed in an immunoradiometric assay (IRMA), in which 125I-labeled antibody was used, and in a more conventional tritiated radioimmunoassay (RIA), in which 3H-paclitaxel was used. RESULTS. Both radioimmunoassays detected levels of paclitaxel in sera that were comparable to those observed with HPLC. However, the IRMA was the most sensitive. Only the IRMA was able to detect low levels of paclitaxel in cerebrospinal fluid after paclitaxel infusion and in sera 3 weeks after infusion. Both the IRMA and RIA methods were able to detect paclitaxel in ascitic and pleural fluids. CONCLUSIONS. Monitoring paclitaxel levels reliably in sera and other bodily fluids is possible with these radioimmunoassays and may be of value in predicting and preventing toxicity and optimizing paclitaxel treatments.

AB - BACKGROUND. Paclitaxel is an antimiotic agent isolated from the Pacific yew tree. It has demonstrated antitumor activity in several cancers and is the first of a new class of antineoplastic agents containing a taxane ring system. Its levels in serum and urine have been measured previously by high performance liquid chromatography (HPLC). In this study, the authors developed two competitive radioimmunoassay methods to determine whether they could reliably be used to measure levels of paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids. METHODS. A monoclonal antibody prepared against paclitaxel was employed in an immunoradiometric assay (IRMA), in which 125I-labeled antibody was used, and in a more conventional tritiated radioimmunoassay (RIA), in which 3H-paclitaxel was used. RESULTS. Both radioimmunoassays detected levels of paclitaxel in sera that were comparable to those observed with HPLC. However, the IRMA was the most sensitive. Only the IRMA was able to detect low levels of paclitaxel in cerebrospinal fluid after paclitaxel infusion and in sera 3 weeks after infusion. Both the IRMA and RIA methods were able to detect paclitaxel in ascitic and pleural fluids. CONCLUSIONS. Monitoring paclitaxel levels reliably in sera and other bodily fluids is possible with these radioimmunoassays and may be of value in predicting and preventing toxicity and optimizing paclitaxel treatments.

KW - carcinoma patients

KW - cerebrospinal fluid

KW - monoclonal antibody

KW - paclitaxel

KW - radioimmunoassay

UR - http://www.scopus.com/inward/record.url?scp=0031040179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031040179&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19970301)79:5<1022::AID-CNCR20>3.0.CO;2-2

DO - 10.1002/(SICI)1097-0142(19970301)79:5<1022::AID-CNCR20>3.0.CO;2-2

M3 - Article

C2 - 9041166

AN - SCOPUS:0031040179

VL - 79

SP - 1022

EP - 1030

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -